Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its acquisition of Advent BioServices Ltd. (“Advent”) has closed. As a result of this acquisition, Advent is now a wholly owned subsidiary of NWBio. As previously announced, through the acquisition of Advent, NWBio is receiving all of Advent’s fixed assets, including extensive cryostorage and other equipment purchased by Advent over the last several years. Intellectual property and other intangibles that Advent had acquired are also included.
Read the full article: Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed //
Source: https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-its-acquisition-of-advent-bioservices-ltd-has-closed-302594108.html